151 related articles for article (PubMed ID: 11460845)
1. [The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice].
De Caterina R
Ital Heart J Suppl; 2001 Jun; 2(6):681-4. PubMed ID: 11460845
[No Abstract] [Full Text] [Related]
2. Low-dose aspirin for primary prevention of cardiovascular disease.
Bredie SJ; Wollersheim H; Verheugt FW; Thien T
Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
[TBL] [Abstract][Full Text] [Related]
3. [Antioxidant vitamins in the treatment and prevention of cardiovascular diseases. Vitamin E].
Spirichev VB
Vopr Pitan; 2003; 72(6):45-51. PubMed ID: 14870590
[TBL] [Abstract][Full Text] [Related]
4. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
Hennekens CH; Sechenova O; Hollar D; Serebruany VL
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
[TBL] [Abstract][Full Text] [Related]
5. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.
de Gaetano G;
Lancet; 2001 Jan; 357(9250):89-95. PubMed ID: 11197445
[TBL] [Abstract][Full Text] [Related]
6. [Low-dosage ASA should not be given as primary prevention. The risk is greater than the benefit--also in high risk of cardiovascular disease].
Håkansson J; Hernborg A
Lakartidningen; 2010 Feb 3-9; 107(5):260-2. PubMed ID: 20297567
[No Abstract] [Full Text] [Related]
7. Randomized trial of aspirin, vitamin E raises questions for future chemoprevention studies.
Hayasaka E
J Natl Cancer Inst; 2005 Sep; 97(17):1242-3. PubMed ID: 16145040
[No Abstract] [Full Text] [Related]
8. [Acetylsalicylic acid does not prevent cardiovascular disease. Poor scientific support for therapeutic guidelines according to primary prevention studies].
Mooe T
Lakartidningen; 2006 Sep 20-26; 103(38):2732-6. PubMed ID: 17058766
[No Abstract] [Full Text] [Related]
9. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
Levy AP; Blum S
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1105-11. PubMed ID: 18035926
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E for the treatment of cardiovascular disease: is there a future?
Violi F; Cangemi R; Sabatino G; Pignatelli P
Ann N Y Acad Sci; 2004 Dec; 1031():292-304. PubMed ID: 15753155
[TBL] [Abstract][Full Text] [Related]
11. Antioxidants are useful in preventing cardiovascular disease: a debate. Pro antioxidants.
Vogel R
Can J Cardiol; 1999 Apr; 15 Suppl B():23B-25B. PubMed ID: 10350680
[TBL] [Abstract][Full Text] [Related]
12. Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial.
Pak RW; Lanteri VJ; Scheuch JR; Sawczuk IS
Integr Cancer Ther; 2002 Dec; 1(4):338-44. PubMed ID: 14664728
[TBL] [Abstract][Full Text] [Related]
13. [Low-dosage acetylsalicylic acid as primary prevention against cardiovascular disease].
Landmark K
Tidsskr Nor Laegeforen; 2001 Jun; 121(16):1937-9. PubMed ID: 11488187
[No Abstract] [Full Text] [Related]
14. [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
Reikvam A; Madsen S; Landmark K
Tidsskr Nor Laegeforen; 2003 Jun; 123(13-14):1838-40. PubMed ID: 12830258
[TBL] [Abstract][Full Text] [Related]
15. [Uncertain benefit of low dosage ASA in peripheral arterial disease. Low dosage in symptomatic--individual assessment in asymptomatic disease].
Norgren L; Bergqvist D; Pärsson H
Lakartidningen; 2010 Jun; 107(23):1534-5. PubMed ID: 20617774
[No Abstract] [Full Text] [Related]
16. [Prevention of stroke with aspirin, vitamin E is ineffective].
Stiefelhagen P
Med Monatsschr Pharm; 2005 Jul; 28(7):249-50. PubMed ID: 16038126
[No Abstract] [Full Text] [Related]
17. Aspirin for the primary prevention of vascular events?
Morgan G
Public Health; 2009 Dec; 123(12):787-8. PubMed ID: 19914670
[No Abstract] [Full Text] [Related]
18. [Antioxidants and cardiovascular disease].
Kazumi T; Yoshino G
Nihon Rinsho; 1999 Dec; 57(12):2837-41. PubMed ID: 10638222
[TBL] [Abstract][Full Text] [Related]
19. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Burger W; Chemnitius JM; Kneissl GD; Rücker G
J Intern Med; 2005 May; 257(5):399-414. PubMed ID: 15836656
[TBL] [Abstract][Full Text] [Related]
20. Advancing the science of aspirin in primary prevention of vascular events.
Cardiovasc J Afr; 2007; 18(5):347-8. PubMed ID: 17985039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
